Adel Seyed Mohammad Hassan, Sardabi Ebrahim Heydari, Akiash Nehzat, Mohammadi Mohammad, Sayadian Mona, Pour Sanaz Saki, Amini Payam
Atherosclerosis Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Department of Cardiology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
J Family Med Prim Care. 2024 Sep;13(9):3931-3937. doi: 10.4103/jfmpc.jfmpc_1964_23. Epub 2024 Sep 11.
The need to understand the global burden of heart failure following the pandemic has arisen as a result of an increase in papers that support cardiac involvement in coronavirus disease 2019 (COVID-19). Therefore, the current study aims to provide a more thorough explanation of the function and use of cardiac biomarkers in dead and alive COVID-19 patients.
All patients who were referred and admitted to Razi Hospital, Ahvaz, Iran, from March 2020 to March 2021 with a diagnosis of COVID-19 were included in this study.
During the study period, 753 patients were hospitalized with a diagnosis of COVID-19. In total, 157 cases died from the disease (case fatality rate: 20.84%). Pre-existing cerebrovascular accidents (CVAs) were more frequent in dead cases (14% vs. 6.4%). It was observed that atrial fibrillation was normal in most of the alive cases in comparison to dead patients ( value = 0.014). Moreover, it was seen that CRP, IL-6, and procalcitonin were increased in dead patients. Also, an association was found between ejection fraction (EF) value and death rate ( value = 0.035). The higher frequency of positive troponin occurring in the dead group suggested a possible adverse effect on the mortality rate (22.3% vs. 16.4%).
Adults with COVID-19 commonly have cardiac manifestations, including symptoms of myocardial damage. In light of the recognized utility of troponin, ejection fraction, procalcitonin, IL-6, and CRP in COVID-19 patients with suspected myocardial damage, we should develop a safe and precise diagnostic algorithm that may contain patients' clinical histories and additional variables that may facilitate the prediction of myopericarditis.
随着支持2019冠状病毒病（COVID-19）心脏受累的论文数量增加，人们开始需要了解疫情后心力衰竭的全球负担。因此，本研究旨在更全面地解释心脏生物标志物在死亡和存活的COVID-19患者中的作用和用途。
本研究纳入了2020年3月至2021年3月期间转诊并入住伊朗阿瓦士拉齐医院且诊断为COVID-19的所有患者。
在研究期间，753例患者因COVID-19住院。共有157例患者死于该疾病（病死率：20.84%）。既往有脑血管意外（CVA）的情况在死亡病例中更为常见（14%对6.4%）。观察发现，与死亡患者相比，大多数存活病例的房颤情况正常（P值=0.014）。此外，还发现死亡患者的CRP、IL-6和降钙素原升高。同时，发现射血分数（EF）值与死亡率之间存在关联（P值=0.035）。死亡组肌钙蛋白阳性频率较高，提示可能对死亡率有不良影响（22.3%对16.4%）。
患有COVID-19的成年人通常有心脏表现，包括心肌损伤症状。鉴于肌钙蛋白、射血分数、降钙素原、IL-6和CRP在疑似心肌损伤的COVID-19患者中的公认效用，我们应制定一种安全、精确的诊断算法，该算法可能包含患者的临床病史和其他可能有助于预测心肌心包炎的变量。
